Allergan USA, Inc. v. MSN Laboratories Private Ltd., Appeal No. 2024-1061 (Fed. Cir. August 13, 2024)
In this week’s Case of the Week, the Federal Circuit clarifies rules relating to when an applicant’s patent can be...more
8/20/2024
/ Appeals ,
Article III ,
Constitutional Challenges ,
EU ,
Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Inventions ,
Inventors ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
SCOTUS
Natera, Inc. v. NeoGenomics Laboratories, Inc., Appeal Nos. 2024-1324, -1409 (Fed. Cir. July 12, 2024)
In its only precedential patent opinion last week, the Federal Circuit affirmed a preliminary injunction that largely...more
Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., Appeal No. 2023-1169 (Fed. Cir. June 25, 2024)
In the Court’s only precedential patent opinion last week, the Federal Circuit reversed the district court’s dismissal of...more
Copan Italia SPA v. Puritan Med. Prods. Co. LLC, Appeal No. 2022-1943 (Fed. Cir. May 14, 2024)
The Federal Circuit’s only precedential opinion concerning a patent case this week had nothing to do with patent law....more
5/21/2024
/ Appeals ,
Coronavirus/COVID-19 ,
Final Judgment ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Motion to Dismiss ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Precedential Opinion
Janssen Pharms., Inc. et al. v. Teva Pharm. USA, Inc. et al., Appeal Nos. 2022-1258, -1307 (Fed. Cir. April 1, 2024)
In this week’s Case of the Week, the Federal Circuit vacated-in-part a district court’s bench trial...more
4/9/2024
/ Abstract Ideas ,
Appeals ,
Claim Construction ,
Janssen Pharmaceuticals ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Prior Art ,
Remand ,
Teva Pharmaceuticals
VLSI Technology LLC v. Intel Corporation, Appeal No. 2022-1906 (Fed. Cir. December 4, 2023)
In this week’s Case of the Week, the Federal Circuit vacated an approximately $2.2 billion damages award against appellant Intel...more
Purdue Pharma L.P. v. Collegium Pharmaceutical, Inc. (United States Patent and Trademark Office intervening), Appeal No. 2022-1482 (Fed. Cir. Nov. 21, 2023)
In the Federal Circuit’s only precedential patent opinion last...more
Baxalta Inc. v. Genentech, Inc., Appeal No. 22-1461 (Fed. Cir. Sept. 20, 2023)
Our Case of the Week focuses on the enablement requirement. It’s the first case to come before the Federal Circuit following the Supreme...more
9/26/2023
/ Amgen ,
Amgen v Sanofi ,
Enablement Inquiries ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Inventions ,
Life Sciences ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
SCOTUS
Amgen Inc. et al. v. Sanofi et al, No. 21-757 (S. Ct. May 18, 2023)
The Supreme Court issued a long-awaited decision today concerning the enablement requirement found in Section 112 of the Patent Act. Specifically, the...more
5/19/2023
/ Amgen ,
Biotechnology ,
Enablement Inquiries ,
Healthcare ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inventions ,
Judicial Proceedings ,
Life Sciences ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sanofi ,
SCOTUS ,
Section 112
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, Appeal No. 2023-1186 (Fed. Cir. Feb. 24, 2023)
In this week’s Case of the Week, the Federal Circuit affirmed a permanent injunction requiring appellant Jazz...more
Mosaic Brands, Inc. v. Ridge Wallet LLC, Appeal Nos. 2022-1001, -1002 (Fed. Cir. Dec. 20, 2022) -
In our Case of the Week, the Federal Circuit discussed the corroboration requirement concerning the amount of evidence...more
12/28/2022
/ Appeals ,
Claim Construction ,
Inequitable Conduct ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-in-Suit ,
Patents ,
Pharmaceutical Patents ,
Reversal ,
Summary Judgment ,
Trade Dress
Provisur Technologies, Inc. v. Weber, Inc., Appeal Nos. 2021-1942, -1975 (Fed. Cir. Sept. 27, 2022) -
In this week’s Case of the Week, the Federal Circuit reviewed an IPR decision and addressed the Patent Trial and Appeal...more
10/4/2022
/ Administrative Procedure Act ,
Alice/Mayo ,
Appeals ,
Claim Limitations ,
Federal Rules of Evidence ,
Inter Partes Review (IPR) Proceeding ,
Motion to Exclude ,
Patent Applications ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art ,
Reversal ,
Vacated
Novartis Pharms. Corp. v. Accord Healthcare, Inc., Appeal No. 2021-1070 (Fed. Cir. June 21, 2022) -
In this week’s Case of the Week, the Federal Circuit granted panel rehearing of and vacated its prior decision in Novartis...more
Niazi Licensing Corporation v. St. Jude Medical SC, Inc., Appeal No. 2021-1864 (Fed. Cir. Apr. 11, 2022) -
The Federal Circuit’s only precedential patent decision this week comes on appeal from a district court decision...more
Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., Appeal No. 2020-2106 (Fed. Cir. Feb. 10, 2022) -
In our Case of the Week, the Court of Appeals for the Federal Circuit, in both the majority opinion and...more
2/15/2022
/ Appeals ,
En Banc Review ,
Inter Partes Review (IPR) Proceeding ,
IP License ,
Motion To Seal ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
Prior Art ,
Remand ,
Third-Party ,
Vacated
Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., Appeal No. 2021-1070 (Fed. Cir. Jan. 3, 2022) -
In this week’s Case of the Week, the Federal Circuit affirmed a district court’s bench trial finding that...more
Intel Corp. v. Qualcomm Inc., Appeal Nos. 2020-1828, -1867 (Fed. Cir. Dec. 28, 2021) -
The Federal Circuit issued two precedential decisions this week—both arising from IPRs filed by Intel against patents owned by...more
1/4/2022
/ Appeals ,
Claim Construction ,
Constitutional Challenges ,
Inter Partes Review (IPR) Proceeding ,
Means-Plus-Function ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art ,
Standing
AstraZeneca AB v. Mylan Pharmaceuticals Inc., Appeal No. 2021-1729 (Fed. Cir. Dec. 8, 2021) -
Our Case of the Week again focuses on numerical values in claims. Last week we addressed a case involving whether there was...more
Biogen International GMBH v. Mylan Pharmaceuticals Inc., Appeal No. 2020-1933 (Fed. Cir. Nov. 30, 2021) -
For the second time in two weeks, our Case of the Week focuses on the written description requirement, in...more
University of Strathclyde v. Clear-Vu Lighting LLC, Appeal No. 2021-2243 (Fed. Cir. Nov. 4, 2021) -
In this week’s Case of the Week, the Federal Circuit reversed an inter partes review decision finding claims directed to...more
11/9/2021
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Dismissals ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Prior Art
Belcher Pharmaceuticals, LLC v. Hospira, Inc., Appeal No. 2020-1799 (Fed. Cir. Sept. 1, 2021) -
In an appeal from the United States District Court for the District of Delaware, the Federal Circuit affirmed the district...more
9/8/2021
/ Appeals ,
Failure To Disclose ,
Food and Drug Administration (FDA) ,
Inequitable Conduct ,
Inventions ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Notice ,
Patents ,
Pharmaceutical Patents ,
Remand ,
Trademarks ,
USPTO
MLC Intellectual Property, LLC v. Micron Technology, Inc., Appeal No. 2020-1413 (Fed. Cir. Aug. 26, 2021) -
For those interested in an important Section 112 written description case, we recommend reading the Juno...more
8/31/2021
/ Appeals ,
Apportionment ,
Damages ,
Discovery ,
Expert Testimony ,
Failure To Disclose ,
Inter Partes Review (IPR) Proceeding ,
Inventions ,
Inventors ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Section 101
Teva Pharms. Int’l GmbH v. Eli Lilly and Co., Appeal Nos. 2020-1747, -1748, -1750 (Fed. Cir. Aug. 16, 2021) -
Eli Lilly and Co. v. Teva Pharms. Int’l GmbH, Appeal Nos. 2020-1876, -1877, -1878 (Fed. Cir. Aug. 16, 2021)...more
Our Case of the Week this week is a re-write of our Case of the Week on October 5, 2020. The case involves a drug that could be used for multiple therapeutic purposes. A patent covered use of the product for a specific...more
8/10/2021
/ Appeals ,
Damages ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Hatch-Waxman ,
Improper Venue ,
Inventions ,
Labeling ,
Liability ,
Motion to Dismiss ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Subject Matter Jurisdiction
Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir. Feb. 11, 2021) -
In this week’s Case of the Week, the Federal Circuit affirmed a district court’s JMOL ruling that asserted claims of two related pharmaceutical patents...more
2/17/2021
/ Appeals ,
Indefiniteness ,
Inter Partes Review (IPR) Proceeding ,
JMOL ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Summary Judgment